Sangamo Therapeutics Inc (NASDAQ:SGMO) price on Friday, November 15, fall -4.65% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.05.
A look at the stock’s price movement, the close in the last trading session was $2.15, moving within a range at $1.96 and $2.185. Turning to its 52-week performance, $3.18 and $0.30 were the 52-week high and 52-week low respectively. Overall, SGMO moved 119.09% over the past month.
Sangamo Therapeutics Inc’s market cap currently stands at around $427.73 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-12.
Analysts have a consensus estimate of 15.85M for the company’s revenue for the quarter, with a low and high estimate of 14M and 17.7M respectively. The average forecast suggests up to a 676.20% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 66.05M, representing a -62.52% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SGMO is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend SGMO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SGMO’s current price about 1.58% and 54.66% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.18, while 7-day volatility ratio is 18.27% and 21.03% in the 30-day chart. Further, Sangamo Therapeutics Inc (SGMO) has a beta value of 1.12, and an average true range (ATR) of 0.34. Analysts have given the company’s stock an average 52-week price target of $12, forecast between a low of $5 and high of $19. Looking at the price targets, the low is -143.9% off current price level while to achieve the yearly target high, price needs to move -826.83%. Nonetheless, investors will most likely welcome a -485.37% jump to $12 which is the analysts’ median price.
If we refocus on Sangamo Therapeutics Inc (NASDAQ:SGMO), historical trading data shows that trading volumes averaged 10.46 over the past 10 days and 7.19 million over the past 3 months. The company’s latest data on shares outstanding shows there are 208.65 million shares.
The 4.60% of Sangamo Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 27.45% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 18.98 million on 2024-10-31, giving us a short ratio of 1.92. The data shows that as of 2024-10-31 short interest in Sangamo Therapeutics Inc (SGMO) stood at 917.0 of shares outstanding, with shares short rising to 18.16 million registered in 2024-09-30. Current price change has pushed the stock 277.32% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SGMO stock continues to rise going into the next quarter.
